Research · Sep 3, 2026
PRAX Praxis Precision Medicines Thesis 2026: Ulixacaltamide Essential Tremor Drives Epilepsy Ion Channel Pipeline Inflection
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) FY2026 thesis centers on continued Ulixacaltamide (Essential Tremor T-Type Calcium Channel) pipeline + Relutrigine + Vormatrigine + Elsunersen Epilepsy pipeline under continued President + CEO Marcio Souza since 2019 (~6-year tenure as Praxis Precision Medicines CEO; selected post-2019 succession from co-founder + selected primary architect of post-2019 NASDAQ IPO October 2020 + selected primary architect of post-2019-2025 selective ion channel modulator R&D platform for epilepsy + movement disorders + CNS — ulixacaltamide + relutrigine + vormatrigine + elsunersen). FY2025 revenue ~$0M (pre-commercial) with adj. EPS ~$-7.50 to $-9.50 reflecting continued clinical development stage status + ~$0.30-0.40B aggregate FY2025 R&D + G&A operating expenses. PRAX operates as 1 primary segment (clinical-stage neuroscience biotech) with 4 clinical-stage assets (ulixacaltamide essential tremor + relutrigine DEE + vormatrigine focal epilepsy + elsunersen SCN2A DEE ASO) + pre-clinical/discovery pipeline. Ulixacaltamide (Essential Tremor T-Type Calcium Channel) pipeline (Lead Asset): selected primary ulixacaltamide (PRAX-944) selective T-type calcium channel inhibitor lead asset in essential tremor (~7-10M aggregate US essential tremor patients + ~1-2M aggregate US essential tremor patients treated/seeking treatment + ~no FDA-approved essential tremor-specific therapies — high unmet need; current off-label propranolol + primidone + topiramate + ~50-70% aggregate inadequate response/intolerance to current off-label therapies) + Essential3 Phase 3 program (Study 1 + Study 2 + open-label extension; ~FY2025-FY2026 expected pivotal data readouts) + ~FY2026-FY2027 expected New Drug Application (NDA) submission to FDA + ~FY2027-FY2028 expected commercial launch potential + ~$1.0-3.0B aggregate analyst consensus essential tremor peak revenue + post-propranolol + primidone + topiramate off-label addressable market displacement. Relutrigine + Vormatrigine + Elsunersen Epilepsy pipeline (Strategic Catalyst): selected primary relutrigine (PRAX-562) sodium channel inhibitor in developmental epileptic encephalopathies (DEEs) — SCN2A + SCN8A + SCN1A + EMBOLD Phase 2 + Phase 3 program + ~FY2025-FY2026 expected data readouts + rare pediatric epilepsy orphan designation + ~$0.5-1.5B aggregate analyst consensus DEE peak revenue + vormatrigine (PRAX-628) selective Nav1.6 inhibitor in focal epilepsy + Phase 2 program + ~FY2026-FY2027 expected data readouts + ~$1.0-3.0B aggregate analyst consensus focal epilepsy peak revenue + elsunersen (PRAX-222) SCN2A antisense oligonucleotide (ASO) in SCN2A developmental epileptic encephalopathies (gain-of-function) + Phase 1/2 program + ~FY2025-FY2026 expected data readouts. Capital position + balance sheet: pre-commercial + no dividend + no buyback + aggregate cash + investments ~$0.40-0.60B (post-2024-2025 equity raise + ~$575M+ aggregate cumulative follow-on equity raises since October 2020 IPO) + ~$0.30-0.40B aggregate FY2025 R&D + G&A operating expense burn rate + ~1.0-1.5 year aggregate cash runway (fully funds through expected ~FY2026 ulixacaltamide Essential3 Phase 3 pivotal data readouts + ~FY2025-FY2026 relutrigine + elsunersen data readouts; ~FY2026 additional capital raise / partnership likely needed for NDA + commercial launch funding) + ~85-90M aggregate diluted shares + fabless biotech model + CDMO contract manufacturing. FY2026 base case pre-commercial + ulixacaltamide Essential3 Phase 3 pivotal data readouts (~FY2025-FY2026 expected) + relutrigine + vormatrigine + elsunersen epilepsy pipeline data readouts + ~$0.40-0.60B aggregate cash + investments + ~$0.35-0.50B aggregate FY2026 R&D + G&A; bull case ulixacaltamide Essential3 Phase 3 Study 1 + Study 2 positive pivotal data (first-in-class essential tremor-specific therapy) + ~FY2026-FY2027 NDA submission + relutrigine EMBOLD Phase 2/3 DEE positive data + vormatrigine Phase 2 focal epilepsy positive data + elsunersen Phase 1/2 SCN2A DEE positive data + strategic M&A/partnership optionality (Cerevel + Karuna + Longboard M&A precedent valuations $8.7B + $14B + $2.6B); bear case ulixacaltamide Essential3 Phase 3 negative/mixed pivotal data (placebo effect + endpoint risk; prior mixed Essential1 data) + relutrigine + vormatrigine + elsunersen Phase 1/2/3 negative data + UCB + Jazz + SK Biopharmaceuticals + Eisai + Marinus + Longboard + Stoke + Encoded competitive intensification + FDA regulatory considerations + commercial launch + payor + access + reimbursement considerations + Cala Health + Insightec + Deep Brain Stimulation device competitive considerations (essential tremor) + capital raise dilution considerations + Phase 1/2/3 clinical trial data risk considerations + post-2019 Marcio Souza CEO succession planning considerations drives ~$0.5-2B market cap compression.